Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704884 | 0.91 | P2RX3 (0.40) | PARP1P2RX3P2RX2TAS2R14ALDH1A1 | |
| SCHEMBL7704973 | 0.86 | RAMP1 (0.35) | PARP1P2RX3P2RX2SMYD3TAS2R14 | |
| SCHEMBL6608132 | 0.81 | CREBBP (0.39) | PARP1P2RX3P2RX2SMYD3 | |
| SCHEMBL7705016 | 0.78 | RAMP1 (0.35) | P2RX3P2RX2SMN1; SMN2 | |
| SCHEMBL7713376 | 0.77 | PARP1 (0.56) | PARP1SMYD3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6305893 | 0.76 | PARP1 (0.54) | PARP1SMYD3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7710997 | 0.75 | PARP1 (0.36) | PARP1ALDH1A1 | |
| SCHEMBL6998344 | 0.75 | PARP1 (0.45) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL7711130 | 0.74 | PARP1 (0.53) | PARP1SMYD3ALDH1A1HTTHTR1A | |
| SCHEMBL6281965 | 0.74 | TMEM97 (0.32) | PARP1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |